Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P32455

UPID:
GBP1_HUMAN

ALTERNATIVE NAMES:
GTP-binding protein 1; Guanine nucleotide-binding protein 1; Interferon-induced guanylate-binding protein 1

ALTERNATIVE UPACC:
P32455; D3DT26; Q5T8M1

BACKGROUND:
Interferon-induced guanylate-binding protein 1 is a key player in the body's immune response to infection. By hydrolyzing GTP to GMP, it activates mechanisms that target and destroy invading pathogens. Its interaction with the ubiquitin-binding protein SQSTM1 and the promotion of autophagy and inflammasome assembly are critical in the host defense against bacterial, viral, and protozoan infections.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Guanylate-binding protein 1 offers promising avenues for therapeutic intervention. Its central role in innate immunity and pathogen defense mechanisms positions it as a potential target for the development of novel treatments aimed at enhancing the body's response to infectious agents.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.